Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.54 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 3/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5499007 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL19088201 | 0.88 | GSR (0.55) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL7294153 | 0.86 | GNAI3 (0.54) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL17982113 | 0.86 | GSR (0.53) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL16430142 | 0.86 | GSR (0.53) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL27921254 | 0.85 | SLC15A1 (0.47) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL28148159 | 0.85 | SLC15A1 (0.47) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL29989156 | 0.84 | GSR (0.57) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL29616781 | 0.83 | SLC15A1 (0.50) | GSRGNAI3GNAO1GNAI1SLC15A1 | |
| SCHEMBL27539919 | 0.83 | GNAI3 (0.70) | GSRGNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | GSR 4171/4885GNAI3 3398/4885GNAO1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.